Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk.

Authors: Lee, Alice W; Ness, Roberta B; Roman, Lynda D; Terry, Kathryn L; Schildkraut, Joellen M; Chang-Claude, Jenny; Doherty, Jennifer A; Menon, Usha; Cramer, Daniel W; Gayther, Simon A; Risch, Harvey; Gentry-Maharaj, Aleksandra; Goodman, Marc T; Modugno, Francesmary; Eilber, Ursula; Moysich, Kirsten B; Berchuck, Andrew; Rossing, Mary Anne; Jensen, Allan; Wicklund, Kristine G; Cushing-Haugen, Kara L; Hogdall, Estrid; Rudolph, Anja; Thompson, Pamela J; Wilkens, Lynne R; Kjaer, Susanne K; Carney, Michael E; Stram, Daniel O; Ramus, Susan J; Wu, Anna H; Pike, Malcolm C; Pearce, Celeste Leigh; Ovarian Cancer Association Consortium

Published In Obstet Gynecol, (2016 05)

Abstract: To describe the association between postmenopausal estrogen-only therapy use and risk of ovarian carcinoma, specifically with regard to disease histotype and duration and timing of use.We conducted a pooled analysis of 906 women with ovarian carcinoma and 1,220 women in a control group; all 2,126 women included reported having had a hysterectomy. Ten population-based case-control studies participating in the Ovarian Cancer Association Consortium, an international consortium whose goal is to combine data from many studies with similar methods so reliable assessments of risk factors can be determined, were included. Self-reported questionnaire data from each study were harmonized and conditional logistic regression was used to examine estrogen-only therapy's histotype-specific and duration and recency of use associations.Forty-three and a half percent of the women in the control group reported previous use of estrogen-only therapy. Compared with them, current or recent estrogen-only therapy use was associated with an increased risk for the serous (51.4%, odds ratio [OR] 1.63, 95% confidence interval [CI] 1.27-2.09) and endometrioid (48.6%, OR 2.00, 95% CI 1.17-3.41) histotypes. In addition, statistically significant trends in risk according to duration of use were seen among current or recent postmenopausal estrogen-only therapy users for both ovarian carcinoma histotypes (Ptrend<.001 for serous and endometrioid). Compared with women in the control group, current or recent users for 10 years or more had increased risks of serous ovarian carcinoma (36.8%, OR 1.73, 95% CI 1.26-2.38) and endometrioid ovarian carcinoma (34.9%, OR 4.03, 95% CI 1.91-8.49).We found evidence of an increased risk of serous and endometrioid ovarian carcinoma associated with postmenopausal estrogen-only therapy use, particularly of long duration. These findings emphasize that risk may be associated with extended estrogen-only therapy use.

PubMed ID: 27054934 Exiting the NIEHS site

MeSH Terms: Carcinoma, Endometrioid/epidemiology*; Carcinoma, Endometrioid/etiology; Cystadenocarcinoma, Serous/epidemiology*; Cystadenocarcinoma, Serous/etiology; Estrogen Replacement Therapy/adverse effects*; Estrogens/therapeutic use; Female; Humans; Menopause*; Ovarian Neoplasms/epidemiology*; Ovarian Neoplasms/etiology; Risk Assessment; Surveys and Questionnaires; United States/epidemiology

to Top